Gilead Begins To Take Advantage Of Its "Global First Refusal" Options, On Assembly Bio's Phase 1b Candidates, In HSV...

This is a very solid publicly traded biopharm company -- just like Moderna, as we mentioned yesterday. And both have been buffeted by Tangerine 2.0 tariff threats, and by Luddite non-scientific vaccine views, from his loopy underling, Kennedy, Jr..

So we believe both are presently trading well below their true fair values [do your own diligence]. This is a nice endorsement for the Assembly Bio folks' approach to treating recurrent herpes strains.

Here's the latest, from Fierce Biotech:

. . .Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact.

Gilead is paying $35 million upfront for the rights to two treatments for recurrent genital herpes, dubbed ABI-1179 and ABI-5366. Both therapies are inhibitors of helicase-primase, an enzyme involved in replication of the herpes virus.

Both assets are currently in phase 1b trials, where they have demonstrated “strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions,” the companies explained. . . .

Now you know, and we are definitely giving very big Black Santa energy here, in the desert this year! Hah!

नमस्ते